Revision as of 22:05, 25 November 2017 by en>JCW-CleanerBot(→Further reading: task, replaced: International Journal of Cancer. Journal International Du Cancer → International Journal of Cancer using AWB)
Along with AHNAK, eIF4E and S100A11, SEPT9 has been shown to be essential for pseudopod protrusion, tumor cell migration and invasion.[5]
Clinical significance
The v2 region of the SEPT9 promoter has been shown to be methylated in colorectal cancer tissue compared with normal colonic mucosa.[6] Using highly sensitive real time PCR assays, methylated SEPT9 was detected in the blood of colorectal cancer patients. This alternate methylation pattern in cancer samples is suggestive of an aberrant activation or repression of the gene compared to normal tissue samples.[7][8]
Testing to detect methylated SEPT9 is not indicated as a first option for colorectal cancer screening.[9] It is similar in specificity and sensitivity to the stool guaiac test or fecal immune tests, and those tests should be used in preference.[9] In cases when the physician aggressively has recommended a colonoscopy and the patient has declined that and these other tests, then this test has advantages over patients having no screening at all.[9]
↑Taki T, Ohnishi H, Shinohara K, Sako M, Bessho F, Yanagisawa M, Hayashi Y (Sep 1999). "AF17q25, a putative septin family gene, fuses the MLL gene in acute myeloid leukemia with t(11;17)(q23;q25)". Cancer Research. 59 (17): 4261–5. PMID10485469.
↑Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR (May 2010). "Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells". Cancer Research. 70 (9): 3780–90. doi:10.1158/0008-5472.CAN-09-4439. PMID20388789.
Pellegrino JE, George RA, Biegel J, Farlow MR, Gardner K, Caress J, Brown MJ, Rebbeck TR, Bird TD, Chance PF (Dec 1997). "Hereditary neuralgic amyotrophy: evidence for genetic homogeneity and mapping to chromosome 17q25". Human Genetics. 101 (3): 277–83. doi:10.1007/s004390050629. PMID9439655.
Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirosawa M, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O (Feb 1999). "Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". DNA Research. 6 (1): 63–70. doi:10.1093/dnares/6.1.63. PMID10231032.
Medina M, Marinescu RC, Overhauser J, Kosik KS (Jan 2000). "Hemizygosity of delta-catenin (CTNND2) is associated with severe mental retardation in cri-du-chat syndrome". Genomics. 63 (2): 157–64. doi:10.1006/geno.1999.6090. PMID10673328.
Kalikin LM, Sims HL, Petty EM (Jan 2000). "Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors". Genomics. 63 (2): 165–72. doi:10.1006/geno.1999.6077. PMID10673329.
Russell SE, McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Petty EM, Kalikin LM, Church SW, McIlroy S, Harkin DP, Keilty GW, Cranston AN, Weissenbach J, Hickey I, Johnston PG (Sep 2000). "Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors". Cancer Research. 60 (17): 4729–34. PMID10987277.
McIlhatton MA, Burrows JF, Donaghy PG, Chanduloy S, Johnston PG, Russell SE (Sep 2001). "Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3". Oncogene. 20 (41): 5930–9. doi:10.1038/sj.onc.1204752. PMID11593400.
Yamamoto K, Shibata F, Yamaguchi M, Miura O (Jun 2002). "Fusion of MLL and MSF in adult de novo acute myelomonocytic leukemia (M4) with t(11;17)(q23;q25)". International Journal of Hematology. 75 (5): 503–7. doi:10.1007/BF02982114. PMID12095151.
Nagata K, Kawajiri A, Matsui S, Takagishi M, Shiromizu T, Saitoh N, Izawa I, Kiyono T, Itoh TJ, Hotani H, Inagaki M (May 2003). "Filament formation of MSF-A, a mammalian septin, in human mammary epithelial cells depends on interactions with microtubules". The Journal of Biological Chemistry. 278 (20): 18538–43. doi:10.1074/jbc.M205246200. PMID12626509.
Nagata K, Asano T, Nozawa Y, Inagaki M (Dec 2004). "Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11". The Journal of Biological Chemistry. 279 (53): 55895–904. doi:10.1074/jbc.M406153200. PMID15485874.
Scott M, Hyland PL, McGregor G, Hillan KJ, Russell SE, Hall PA (Jul 2005). "Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours". Oncogene. 24 (29): 4688–700. doi:10.1038/sj.onc.1208574. PMID15782116.
Ito H, Iwamoto I, Morishita R, Nozawa Y, Narumiya S, Asano T, Nagata K (Oct 2005). "Possible role of Rho/Rhotekin signaling in mammalian septin organization". Oncogene. 24 (47): 7064–72. doi:10.1038/sj.onc.1208862. PMID16007136.
Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE (Mar 2006). "Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis". International Journal of Cancer. 118 (5): 1325–9. doi:10.1002/ijc.21486. PMID16161048.
Kuhlenbäumer G, Hannibal MC, Nelis E, Schirmacher A, Verpoorten N, Meuleman J, Watts GD, De Vriendt E, Young P, Stögbauer F, Halfter H, Irobi J, Goossens D, Del-Favero J, Betz BG, Hor H, Kurlemann G, Bird TD, Airaksinen E, Mononen T, Serradell AP, Prats JM, Van Broeckhoven C, De Jonghe P, Timmerman V, Ringelstein EB, Chance PF (Oct 2005). "Mutations in SEPT9 cause hereditary neuralgic amyotrophy". Nature Genetics. 37 (10): 1044–6. doi:10.1038/ng1649. PMID16186812.